JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M411555200 on November 23, 2004

J. Biol. Chem., Vol. 280, Issue 4, 2954-2961, January 28, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/4/2954    most recent
M411555200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cai, L.
Right arrow Articles by van der Westhuyzen, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cai, L.
Right arrow Articles by van der Westhuyzen, D. R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Serum Amyloid A Is a Ligand for Scavenger Receptor Class B Type I and Inhibits High Density Lipoprotein Binding and Selective Lipid Uptake*

Lei Cai, Maria C. de Beer, Frederick C. de Beer, and Deneys R. van der Westhuyzen{ddagger}

From the Department of Internal Medicine, Graduate Center for Nutritional Sciences, University of Kentucky Medical Center, Lexington, Kentucky 40536 and the Department of Veterans Affairs Medical Center, Lexington, Kentucky 40511

Received for publication, October 12, 2004 , and in revised form, November 23, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Serum amyloid A is an acute phase protein that is carried in the plasma largely as an apolipoprotein of high density lipoprotein (HDL). In this study we investigated whether SAA is a ligand for the HDL receptor, scavenger receptor class B type I (SR-BI), and how SAA may influence SR-BI-mediated HDL binding and selective cholesteryl ester uptake. Studies using Chinese hamster ovary cells expressing SR-BI showed that 125I-labeled SAA, both in lipid-free form and in reconstituted HDL particles, functions as a high affinity ligand for SR-BI. SAA also bound with high affinity to the hepatocyte cell line, HepG2. Alexa-labeled SAA was shown by fluorescence confocal microscopy to be internalized by cells in a SR-BI-dependent manner. To assess how SAA association with HDL influences HDL interaction with SR-BI, SAA-containing HDL was isolated from mice overexpressing SAA through adenoviral gene transfer. SAA presence on HDL had little effect on HDL binding to SR-BI but decreased (30–50%) selective cholesteryl ester uptake. Lipid-free SAA, unlike lipid-free apoA-I, was an effective inhibitor of both SR-BI-dependent binding and selective cholesteryl ester uptake of HDL. We have concluded that SR-BI plays a key role in SAA metabolism through its ability to interact with and internalize SAA and, further, that SAA influences HDL cholesterol metabolism through its inhibitory effects on SR-BI-mediated selective lipid uptake.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Serum amyloid A (SAA)1 is a plasma protein whose concentration increases by as much as 1000-fold or more during the acute phase response following bacterial infection, tissue damage, and inflammation (1, 2). SAA is produced mainly in the liver where it is induced by cytokines, primarily interleukin-1, tumor necrosis factor {alpha}, and interleukin-6 (1). During the acute phase response, SAA synthesis can account for as much as 2.5% of total protein production in the liver and plasma SAA levels can exceed 1 mg/ml, implying a beneficial role of SAA in host defense. SAA synthesis induced by inflammatory stimuli has also been detected in adipocytes, intestinal epithelial cells, and muscle cells (1). SAA is a precursor of amyloid A protein, the principal component of reactive systematic amyloid that may be deposited in organs as a result of chronic inflammatory disease (3).

The SAA gene family is highly conserved in mammals and in humans consists of four closely related genes; SAA1 and SAA2 encode for the acute phase proteins SAA1 and SAA2, SAA3 is a pseudogene, and SAA4 encodes the constitutively expressed SAA that is found in low levels in both normal and acute phase plasma (1, 3). The mouse Saa1 and Saa2 genes are evolutionary homologues of the human SAA1 and SAA2 genes, respectively. Unlike human SAA3, mouse Saa3 is expressed as a protein. Interestingly, expression of mouse Saa3 is largely extrahepatic and has been demonstrated in macrophages and other non-hepatic cells (4). Mouse Saa4, like human SAA4, is a constitutively expressed protein (5). The acute phase SAA1 and SAA2 are allelic, giving rise to three distinct SAA1 proteins (SAA1.1-SAA1.3) and two SAA2 proteins (SAA2.1 and SAA2.2). SAA shares many structural features with other apolipoproteins, including an amphipathic {alpha}-helix at the amino terminus that may be responsible for binding SAA to HDL. Both acute phase and constitutively expressed SAAs associate strongly with HDL and are present in the plasma largely as apolipoproteins of HDL3 (6). During the acute phase response, SAA can replace apoA-I as the major HDL apolipoprotein (6).

The biological function of SAA remains unclear (reviewed in Refs. 1 and 2). A number of studies have suggested a role of SAA in the inflammatory process, probably acting via the G-protein-coupled receptor FPRL1 (7). In line with its association with HDL, it is plausible that SAA might regulate the role of HDL in reverse cholesterol transport. SAA has been reported in some (8–10), but not all (11), studies to promote cholesterol efflux from cells such as macrophages to HDL. Mouse Saa2.1 (but not Saa1.1) is able to inhibit intracellular cholesterol esterification in macrophages while at the same time activating neutral cholesterol esterase and hence cholesterol ester (CE) hydrolysis (9). Such effects, together with enhanced binding of acute phase HDL to macrophages (11, 12) could promote free cholesterol efflux from cells and facilitate cholesterol removal from sites of tissue damage. An alternative hypothesis is that SAA promotes cholesterol delivery to cells during tissue repair. SAA binds cholesterol and can transport cholesterol into macrophages (13). Increased HDL binding to macrophages might also promote HDL cholesterol uptake into these cells (11). These possibilities and their underlying mechanisms remain to be clarified.

The scavenger receptor SR-BI is an HDL receptor that mediates the cellular uptake of CE from HDL by a mechanism known as selective lipid uptake (14, 15). SR-BI in the liver plays a key role in the clearance of HDL CE, thereby facilitating the process of reverse cholesterol transport from the periphery to the liver. SR-BI also facilitates the efflux of cellular-free cholesterol to HDL. The receptor exhibits a broad ligand binding specificity and binds LDL, oxidized LDL, and very low density lipoprotein in addition to HDL (14). Anionic phospholipids bind to SR-BI, as do the apolipoproteins A-I, A-II, C-III, and E, either as lipid-bound molecules or as free apolipoproteins. The effect of SAA on HDL binding and selective lipid uptake by SR-BI has not been investigated. In this study we have demonstrated that both lipid-free and lipid-bound SAA is bound and internalized by SR-BI and that SAA exerts an inhibitory effect on HDL binding and selective lipid uptake.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Materials—L-{alpha}-palmitoyloleoylphosphatidylcholine, crystalline cholesterol, sodium cholate, and fatty acid free bovine serum albumin (BSA) were purchased from Sigma. Human ApoA-I and human SAA (recombinant human SAA, corresponding to human SAA1 {alpha} except for the presence of an N-terminal methionine and substitution of asparagine for aspartic acid at position 60 and arginine for histidine at position 71) were purchased from Biodesign (Saco, ME). The Alexa fluorescent labeling kits were from Molecular Probes (Eugene, OR).

Animals—C57BL/6 mice were purchased from Jackson Laboratory, Bar Harbor, ME. Mouse SAA overexpression was obtained by tail vein injection of a second generation recombinant adenovirus expressing the mouse CE/J isoform of Saa that closely resembles both Saa1 and Saa2 (16). The SAA adenovirus, AdSAA, was prepared as described previously (17). 4 x 1011 particles of AdSAA adenovirus or Ad-null virus (a virus containing no transgene) were injected into each mouse. Animals were taken 72 h after virus infusion, blood was collected by cardiac puncture, and HDL was isolated as described below. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee (Veterans Affairs Medical Center, Lexington, KY).

Cell Culture—Stable transfectants of CHO cells expressing human SR-BI (CHO-SR-BI cells) were generated as described elsewhere (18) and cultured in medium containing 0.25 g/liter geneticin (Invitrogen). CHO cells were grown in Hams F12 medium supplemented with 5% (v/v) heat-inactivated fetal bovine serum, 2 mM L-glutamine, 50 units/ml penicillin G, and 50 µg/ml streptomycin. Clones were screened for expression of the scavenger receptors by immunoblotting with a rabbit polyclonal antibody recognizing the extracellular domain of SR-BI (18). For biochemical assays, CHO cells were grown in 12-well clusters (Corning Corp., Corning, NY). For microscopy, CHO cells were grown on glass coverslips.

Isolation and Radiolabeling of HDL—HDL3 was isolated from human plasma as described previously (19). Briefly, HDL3 (d = 1.13–1.18) was isolated from EDTA anti-coagulated human blood. Mouse HDL (d = 1.063–1.21) was isolated from EDTA anti-coagulated blood obtained by cardiac puncture from metofane-anesthetized mice. HDLs were isolated by sequential ultracentrifugation, dialyzed against 150 mM NaCl, 2.5 mM EDTA (pH 7.4), sterile filtered, and stored under nitrogen gas at 4 °C. Protein was determined by the method of Lowry. HDL was iodinated by the iodine monochloride method as described before (20). The specific activity of the free apolipoproteins ranged from 101 to 132 cpm/ng protein, and the specific activity for reconstituted HDL (rHDL) ranged from 143–395 cpm/ng protein. For studies involving selective lipid uptake, HDL was double-labeled by iodination of the protein component and by tracing the CE component with nonhydrolyzable, intracellularly trapped [1,2(n)-3H] cholesterol oleyl ether as described previously (20). Briefly, [1,2(n)-3H]cholesteryl oleyl ether was dried in a 12 x 75-mm borosilicate glass tube (20 µCi/mg HDL protein), after which HDL and partially purified cholesteryl ester transfer protein were added. Following 16 h of incubation at 37 °C, HDL was re-isolated by ultracentrifugation at a density of 1.21 g/ml. The specific activity of the 125I-protein component of HDL ranged from 144 to 196cpm/ng protein. The specific activity of the [3H]CE-HDL ranged from 10 to 17 dpm/ng protein. The integrity of radiolabeled HDL preparations was verified by SDS-PAGE and non-denaturing gradient gel electrophoresis.

Ligand Binding and Uptake Assays—Cell association assays were performed as described previously (18, 21). Briefly, cells were seeded into 12-well cell culture clusters at an initial density of 1 x 105 cells/cm2. When the cells reached confluency, they were washed with phosphate-buffered saline and incubated at 37 °C for the indicated times with radiolabeled ligands in Hams-F12 medium containing 50 units/ml penicillin, 50 units/ml streptomycin, 2 mM glutamine, and 0.5% BSA. For 4 °C binding, cells were preincubated in the above medium at 37 °C for 1 h, washed twice with ice-cold buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4, 0.2% BSA), and then incubated with HEPES-buffered Ham-F12 medium containing 0.5% BSA. At the end of the binding experiments, medium was removed and the cells were washed four times with cold buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) containing BSA (2 mg/ml) followed by two washes in the same buffer without BSA. The cells were then solubilized in 0.1 N NaOH for 60 min at room temperature, and the protein and 125I content of the lysate were determined. [3H]CE content was determined after lipid extraction. Cell association values are expressed as apparent HDL protein uptake assuming the uptake of intact holoparticles. Ligand degradation products in the culture medium were assayed as described (21). Selective uptake is defined as 3H - (125I cell-associated + 125I degraded) and represents the uptake of cholesteryl ester that cannot be accounted for by the internalization of intact particles. SR-BI-specific values were calculated as the difference between the values for CHO-SR-BI and untransfected CHO cells (CHO-A7). Kd values were determined by non-linear regression analysis of receptor-specific cell association values using Prism software (GraphPad Software, San Diego, CA).

Preparation of rHDL—Reconstituted HDL containing palmitoyloleoylphosphatidylcholine and apoA-I or SAA were prepared by the sodium cholate dialysis method as described previously (21, 22). Briefly, human apoA-I or human SAA were prepared using molar ratios of 1/5/95, apolipoprotein/free cholesterol/palmitoyloleoylphosphatidylcholine. The purity and size of rHDL were examined on 8–25% gradient gels under non-denaturing conditions using the Amersham Biosciences Phast system. Protein concentrations of lipid-free or lipid-bound apoA-I and SAA were determined by the Lowry assay. Experiments were performed within 7 days of particle preparation to avoid time-dependent size rearrangement of particles.

Cell Association and Uptake of Fluorescent-labeled Apolipoproteins— Human apoA-I/SAA reconstituted HDLs or free apolipoproteins were labeled with Alexa according to the manufacturer's (Molecular Probes) instructions. Briefly, apolipoproteins were incubated with Alexa 488 (green fluorescence) or Alexa 568 (red fluorescence) for 1 h at room temperature (1 mg protein/vial dye). Fluorescently labeled proteins were purified using a 30-mm resin column and stored at 4 °C under N2 gas. Cells were grown on glass coverslips until 50–70% confluent and then incubated in serum-free medium containing 0.5% BSA for 1 h at 37 °C before the addition of Alexa-labeled SAA or apoA-I in 0.5% BSA-containing medium for another 2 h. Cells were then washed five times with cold PBS containing 1 mM CaCl2 and 1 mM MgCl2 and fixed in 1% paraformaldehyde in PBS. The cells were then mounted on glass slides with VECTASHIELD mounting medium (Vector Labs, Burlingame, CA) and analyzed with an Olympus BX51 fluorescence microscope or a Leica TCS confocal laser scanning fluorescence microscope. In any given experiment, all pictures were identically exposed and processed.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
The ability of SAA to function as a ligand for the HDL receptor SR-BI was tested using rHDL. rHDL containing palmitoyloleoylphosphatidylcholine was prepared as this phospholipid is not a ligand for SR-BI (23). Fig. 1 shows that 125I-labeled recombinant human SAA1 in reconstituted particles (SAA-rHDL) exhibited receptor-specific, saturable, and high affinity binding (Kd = 17 ± 1.3 µg/ml) at 4 °C to SR-BI expressed in CHO cells. Apo-AI in reconstituted particles (AI-rHDL) also functioned as a high affinity SR-BI ligand (Kd = 4.0 ± 0.4 µg/ml) as previously reported (21). The affinity of both SAA-rHDL and AI-rHDL was greater than the affinity observed for native HDL3 particles (Kd = 40 µg/ml, data not shown). Maximal binding of SAA-rHDL (Bmax = 2000 ± 63 µg/ml) was greater than that of AI-rHDL (Bmax = 792 ± 21 µg/ml). High affinity association to SR-BI was also observed at 37 °C for both SAA-rHDL (apparent Kd = 12.5 ± 1.2 µg/ml) and AI-rHDL (apparent Kd = 5.4 ± 0.7 µg/ml) (Fig. 2). At 37 °C, SAA-rHDL showed greater association with control CHO-A7 cells (15–30% of the value in CHO-SR-BI cells) than apoA-I, indicating that a component of SAA cell association in CHO cells was SR-BI-independent. As in the case of CHO-SR-BI cells, SAA-rHDL also showed high affinity association to HepG2 cells (data not shown). Relative to the amounts of cell-associated ligand in these experiments, only small amounts of apolipoprotein ligand were degraded during incubation at 37 °C for 2 h. A greater fraction of ligand degradation occurred in the case of SAA-rHDL (16% of cell-associated ligand) than for AI-rHDL (8% of cell-associated ligand). This indicated a greater degree of ligand internalization and degradation of SAA-rHDL compared with AI-rHDL (see also Fig. 3B).



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 1.
Binding of SAA-rHDL and AI-rHDL to SR-BI. Cells were incubated at 4 °C for 2 h with 125I-labeled SAA-rHDL and AI-rHDL as described under "Materials and Methods." SR-BI-specific values are shown (solid lines) and are calculated as the difference between values for CHO-SR-BI cells and non-transfected CHO-A7 cells (dotted lines). Values in CHO-A7 cells were less than 10% of the corresponding values in CHO-SR-BI cells for both ligands. Values represent the mean ± S.D. of triplicate determinations in one of two representative experiments using two preparations of ligand.

 



View larger version (21K):
[in this window]
[in a new window]
  		FIG. 2.
Cell association and selective uptake of SAA-rHDL and AI-rHDL by SR-BI. Cells were incubated at 37 °C for 2 h with 125I-labeled SAA-rHDL and AI-rHDL as described under "Materials and Methods." SR-BI-specific values are shown (solid lines) and are calculated as the difference between values for CHO-SR-BI cells and non-transfected CHO-A7 cells (dotted lines). Values for SAA-rHDL in CHO-A7 cells varied between 15 and 30% of the corresponding values in CHO-SR-BI cells in three experiments. Values represent the mean ± S.D. of triplicate determinations for one of three representative experiments using two preparations of ligand.

 



View larger version (45K):
[in this window]
[in a new window]
  		FIG. 3.
Binding and internalization of fluorescently labeled human SAA and apoA-I by SR-BI. CHO-SR-BI and CHO-A7 cells were incubated with 10 µg/ml Alexa-labeled AI-rHDL (A) or SAA-rHDL (C) at 4 °C for 2 h or with 5 µg/ml Alexa-labeled AI-rHDL (B) or SAA-rHDL (D) at 37 °C for 2 h. No significant cell association of ligands was observed in CHO-A7 cells (inserts).

 
Binding of SAA to SR-BI was also investigated by fluorescence microscopy using fluorescently labeled apolipoproteins in rHDL. Both Alexa-labeled AI-rHDL and Alexa-labeled SAA-rHDL exhibited SR-BI-dependent cell surface binding to CHO-SR-BI cells at 4 °C, with little or no binding being observed in control CHO-A7 cells (Fig. 3, A and C, inserts). Similarly, at 37 °C, SR-BI-dependent cell association of both AI-rHDL and SAA-rHDL occurred (Fig. 3, B and D). In the case of AI-rHDL, ligand was most prominent at the cell surface, consistent with a mechanism in which SR-BI mediates HDL-selective uptake at the cell surface (24–26). Small punctate accumulations of ligand were also observed intracellularly. Interestingly, SAA-rHDL was observed not only at the cell surface but also in relatively large amounts in prominent intracellular punctate spots, demonstrating a markedly greater internalization and accumulation of the SAA-containing ligand compared with apoA-I-containing particles.

We next addressed the question of whether the presence of SAA on HDL affects HDL binding and selective lipid uptake by SR-BI. The approach employed was to generate HDL enriched with mouse SAA (AdSAA-HDL) in mice through adenovirus-mediated gene transfer as described previously (17). The composition and apolipoprotein content of AdNull-HDL and Ad-SAA-HDL are shown in Fig. 4A and Table I. HDL from control mice (injected with AdNull, an adenoviral vector that does not express a protein product) contained no detectable SAA, whereas AdSAA-HDL contained significant amounts of SAA as is typical during an acute phase response (Fig. 4A). The composition of AdSAA-HDL was distinguished from control HDL by an elevated level of unesterified cholesterol (11.1 versus 6.0% by weight) and a decreased level of CE (7.6 versus 12.3% by weight). Phospholipid and protein contents of the two HDLs were similar. The reduced content of esterified cholesterol is likely due in part to the known inhibitory effect of SAA on lecithin:cholesterol acyltransferase activity (9, 27). The association of double labeled 125I-/[3H]CE-AdSAA-HDL and AdNull-HDL to SR-BI were similar, with AdSAA-HDL showing slightly greater association only at the higher ligand concentrations examined (Fig. 4B). Selective CE uptake was also examined for the two ligands. Selective uptake from AdSAA-HDL was found to be 30–50% less than that observed for AdNull-HDL. These results indicated that the presence of SAA on HDL negatively influences selective lipid uptake from HDL, despite increased cell association of the ligand.



View larger version (22K):
[in this window]
[in a new window]
  		FIG. 4.
Cell association and selective CE uptake of AdSAA-HDL and control AdNull-HDL by SR-BI. A, SDS-PAGE analysis of AdSAA-HDL (5 µg/lane) and AdNull-HDL (5 µg/lane). HDL was isolated from C57BL/6 mice injected with either AdNull or AdSAA adenovirus as described under "Materials and Methods." B and C, cell association (B) and selective CE uptake (C) of AdSAA-HDL and AdNull-HDL by SR-BI. CHO-SR-BI and CHO-A7 cells were incubated with 125I-/[3H]AdSAA-HDL and 125I-/[3H]CE-AdNull-HDL at 37 °C for 2 h. The cell associated 125I-HDL protein and selective uptake of [3H]CE was quantified as described under "Materials and Methods." SR-BI-specific values are shown and calculated as the difference between values for CHO-SR-BI cells and CHO-A7 cells. Values represent the mean ± S.D. of triplicate determinations for one of two representative experiments using two preparations of ligand.

 


View this table:
[in this window]
[in a new window]
  		TABLE I
Composition of AdNull-HDL and AdSAA-HDL Protein concentration was determined by the method of Lowry. Free cholesterol (FC), cholesterol ester (CE), triglyceride (TG), total cholesterol (TC) were determined enzymatically using commercially available kits (WAKO Chemicals, Richmond VA). Values represent the mean ± S.D. of four experiments (n = 4).

 
Lipid-free apolipoproteins also bind to SR-BI (23), although lipid-free apoA-I binds poorly compared with lipid-associated apoA-I (28). Given the fact that SAA is secreted in relatively large amounts from hepatocytes likely in a lipid-free form during an acute phase response (29), we investigated whether lipid-free SAA binds to SR-BI and whether such binding influences HDL binding and selective lipid uptake by SR-BI. Similar to SAA-rHDL, Alexa-labeled lipid-free SAA bound specifically at 4 °C to SR-BI at the cell surface of CHO-SR-BI cells (Fig. 5C), with little binding being observed in the untransfected CHO-A7 cells (Fig. 5C, insert). SR-BI-specific cell surface binding at 4 °C was also seen in the case of lipid-free apoA-I (Fig. 5A). Lipid-free SAA was internalized at 37 °C by CHO cells in an SR-BI-dependent manner (Fig. 5D). In contrast, lipid-free apoA-I showed little internalization at 37 °C with the large bulk of cell-associated fluorescent apolipoprotein being bound to the cell surface (Fig. 5B).



View larger version (47K):
[in this window]
[in a new window]
  		FIG. 5.
Binding of fluorescently labeled lipid-free human SAA or lipid-free apoA-I to SR-BI. CHO-SR-BI and CHO-A7 cells were incubated at 4 °C for 2 h with 20 µg/ml Alexa-labeled lipid-free apoA-I (A) or lipid-free SAA (C) or with 10 µg/ml Alexa-labeled lipid-free apoA-I (B) or lipid-free SAA (D) at 37 °C for 2 h. No significant cell association of ligands was observed in CHO-A7 cells (inserts).

 
We next assessed whether lipid-free SAA modulates normal HDL association or selective CE uptake by SR-BI. Unexpectedly, and in contrast to lipid-free apoA-I, lipid-free SAA exerted a marked inhibitory effect on HDL association and selective lipid uptake by SR-BI when added even at relatively low concentrations (1–2 µg/ml) to the HDL-containing assay medium (Fig. 6A). At a concentration of 5 µg/ml, SAA inhibited SR-BI-specific cell association of HDL (10 µg/ml) by ~50%. Lipid-free SAA had a similar inhibitory effect on SR-BI-mediated selective lipid uptake (Fig. 6B). SAA at a concentration of 10 µg/ml inhibited selective CE uptake by ~70% (68 ± 14% in five experiments). In contrast, apoA-I showed no significant inhibitory effect on either HDL association or selective cholesterol ester uptake at the highest concentration used (10 µg/ml). A marked inhibition of selective lipid uptake by SAA was also found in HepG2 cells (Fig. 6C). SAA did not appear to have a general toxic effect on cells based on trypan blue staining and viability following exposure to SAA. These results showed that lipid-free SAA, unlike lipid-free apoA-I, exerts a marked inhibitory effect on HDL cell association and selective lipid uptake.



View larger version (13K):
[in this window]
[in a new window]
  		FIG. 6.
Effect of SAA on HDL association and selective CE uptake by SR-BI. A and B, CHO-SR-BI cells were incubated at 37 °C for 2 h with 125I-/[3H]CE-HDL3 (10 µg/ml) in the presence of the indicated amounts of lipid-free human SAA (closed circles) or apoA-I (open circles). SR-BI-specific values were calculated as the difference between values for CHO-SR-BI cells and untransfected CHO-A7 cells. C, HepG2 cells were assayed as described for CHO-SR-BI cells. Cell-associated 125I-HDL protein and selective uptake of [3H]CE was quantified as described under "Materials and Methods." Values represent the mean ± S.D. of triplicate determinations. Similar results were obtained in four experiments. Values are expressed as a percentage of the value obtained in the absence of SAA. Values in the absence of SAA: A, cell association = 63.2 ± 12.8 ng of HDL protein/mg cell protein; B, selective uptake = 1551.0 ± 222.8 ng of HDL protein/mg cell protein; C, selective uptake = 369.7 ± 78.9 ng of HDL protein/mg cell protein.

 
Lipid-free SAA also markedly inhibited the binding of HDL to CHO-SR-BI cells at 4 °C (Fig. 7A). This provided evidence that the inhibitory effect of SAA was not the result of an SAA-induced alteration in the number of cell surface SR-BI receptors at 37 °C, for example, through an alteration of the cellular distribution of SR-BI receptors in response to SAA. Another mechanism by which SAA might affect HDL binding and selective uptake is through its association with HDL and a consequent remodeling of the resulting SAA-containing HDL particles. For example, SAA associates strongly with HDL and can displace apoA-I from HDL particles (6). Interestingly, when SAA was incubated with the radiolabeled HDL ligand at 4 °C for 30 min before the HDL was added to cells (premix HDL + SAA), no significant inhibitory effect of SAA on the 4 °C binding of HDL by SR-BI was observed (Fig. 7A). Similarly, incubating SAA with HDL ligand at 37 °C for 30 min before assaying for HDL association and selective lipid uptake at 37 °C did not lead to any significant alteration either in HDL cell association (Fig. 7B) or selective CE uptake (Fig. 7C). This was in contrast to the marked inhibitory effects of SAA when added to the HDL ligand at the start of the assay period. The inhibitory effect of SAA on selective CE uptake was decreased with increasing time of preincubation of SAA with HDL as shown in Fig. 8. These results provided evidence that the inhibitory effect of SAA on SR-BI-mediated HDL binding and selective uptake is not because of SAA-induced remodeling of HDL particles but rather because of its ability to interact directly with SR-BI.



View larger version (13K):
[in this window]
[in a new window]
  		FIG. 7.
Inhibition of SR-BI-specific HDL association and selective lipid uptake by SAA in CHO cells. A, HDL binding to SR-BI at 4 °C. Cells were incubated at 4 °C for 2 h with 125I-/[3H]CE-HDL3 (10 µg/ml) in the presence or absence of human SAA (10 µg/ml). In the "Premix HDL + SAA" groups, HDL and SAA were incubated together in the assay medium for 30 min at 4 °C before addition to cells. B and C, HDL cell association and selective CE uptake by SR-BI. Cells were incubated at 37 °C for 2 h with 125I-/[3H]CE-HDL3 (10 µg/ml) in the presence or absence of human SAA (10 µg/ml). In the "Premix HDL + SAA" groups, HDL and SAA were incubated together in the assay medium for 30 min at 37 °C before addition to cells. SR-BI-specific values are expressed as a percentage of the control value obtained in the absence of SAA. Values represent the mean ± S.D. of triplicate determinations. Similar results were obtained in three experiments.

 



View larger version (17K):
[in this window]
[in a new window]
  		FIG. 8.
Effect of premixing with HDL on SAA inhibition of SR-BI-selective uptake. 10 µg/ml of SAA or apoA-I together with 10 µg/ml of 125I-/[3H]CE-HDL were premixed at 37 °C for the indicated time periods prior to addition to cells. Selective uptake assays were carried out as described in the legend to Fig. 7. Similar results were obtained in two additional experiments.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Reconstituted lipoprotein particles containing 125I-labeled human SAA were used to demonstrate that SAA functions as a high affinity ligand for SR-BI expressed in CHO cells. Although the affinity of SAA-rHDL for SR-BI was lower than that of AI-rHDL, both types of particles displayed affinities greater than that of HDL, as we have previously reported for AI-rHDL (21, 30). Differences between apoA-I conformation in the lipid-free form and in different sized HDLs appear to account for the marked differences in binding of these apoA-I-containing ligands (30). At 37 °C, both SAA-rHDL and AI-rHDL showed high affinity association to SR-BI-expressing cells, and microscopic studies using fluorescently labeled SAA and apoA-I confirmed receptor-specific binding of SAA at the cell surface. Similarly, SAA-rHDL exhibited high affinity binding to HepG2 cells that are known to express SR-BI. The ability of SAA to serve as a high affinity SR-BI ligand is in line with the ability of SR-BI to bind other HDL apolipoproteins such as apoA-I, A-II, C-III, and apoE (14). A model class A amphipathic {alpha}-helix was shown to bind SR-BI with high affinity, suggesting that multiple amphipathic {alpha}-helical sites on apoA-I or other apolipoproteins may mediate binding to SR-BI (31). SAA contains two {alpha}-helical regions, and the amino terminus is a short amphipathic {alpha}-helix (32) that is likely involved in lipid binding.

In addition to binding SAA, SR-BI also mediated the internalization of both apoA-I and SAA in reconstituted HDLs. However, internalization of SAA was markedly greater than that of apoA-I, which as previously reported is internalized at a very low rate in CHO cells (24–26). The pathway responsible for the internalization of SR-BI and its ligands has not been described in detail. Thus, the extent of HDL particle uptake by SR-BI and the role of particle uptake in the process of selective lipid uptake has not been defined (14, 15). SR-BI-mediated internalization of apoA-I from HDL has been shown in both murine and human hepatocytes (33) and Madin-Darby canine kidney cells (34). However, little if any SR-BI-mediated uptake of HDL particles or apolipoproteins is observed in CHO cells (25, 26) or steroidogenic cells (25, 35), in which SR-BI levels and rates of HDL-selective uptake are high. In such cells, therefore, selective uptake does not appear to depend on internalization. In hepatocytes, apoA-I is internalized by SR-BI into a juxtanuclear region that contains transferrin and corresponds to the endosomal recycling compartment (34). Internalization is not inhibited by clathrin or dynamin dominant-negative mutants and thus does not appear to require clathrin-coated pits or caveolae (34). In addition to HDL, SR-BI also mediates the uptake of other ligands such as AGE-BSA, M-BSA, LDL, and oxLDL (14). Interestingly, such ligands may be sorted differently following cellular uptake. For example, AGE-BSA is degraded in lysosomes (36), whereas M-BSA is not (37). Our results clearly demonstrated greater uptake of SAA compared with apoA-I. The pathway and mechanisms involved in such uptake require further studies.

Human acute phase SAA, but not the constitutive SAA4 isoform, binds cholesterol and mediates the uptake of unesterified cholesterol into HepG2 cells and smooth muscle cells (13). Our finding that SR-BI efficiently takes up SAA into cells makes this receptor a likely candidate responsible for such SAA uptake by cells. A role for SAA endocytosis has also been proposed to explain the increased ability of acute phase HDL to promote cellular cholesterol efflux from cholesterol-laden macrophages (10, 38, 39), but not from non-lipid-loaded macrophages (11, 27, 40). Internalization of SAA in macrophages has been shown and internalized mouse Saa2.1- or Saa2.1-derived peptides have been reported to inversely regulate intracellular ACAT and cholesterol esterase activities in a manner that elevates cellular-free cholesterol levels and consequently stimulates cellular cholesterol efflux (10, 39). SAA uptake into macrophages is strongly dependent on cell surface heparan sulfate binding to SAA (41) and occurs via a clathrin-dependent pathway (41). SR-BI is expressed in activated macrophages (42), but its contribution in these cells to HDL-selective lipid uptake, or SAA uptake, is unclear.

The binding and uptake of SAA by SR-BI suggests that this receptor, which is highly expressed in hepatocytes, may play a key role in the plasma clearance and catabolism of SAA. Plasma SAA and apoA-I are known to be catabolized at markedly different rates, with SAA having a far shorter half-life (t1/2 ~ 80 min) than that of apoA-I (t1/2 ~ 11 h) (43). Later studies showed a more rapid catabolism for Saa1 than Saa2 in mice (44). ApoA-I is largely cleared in the liver, with the kidneys also contributing to a significant extent (45). SAA is more rapidly cleared than apoA-I in perfused liver (46), but the main tissue site of plasma SAA clearance is not known. The mechanisms and putative receptors responsible for apoA-I or SAA clearance have not been described.

To test how the presence of SAA on HDL might influence HDL interaction with SR-BI, we overexpressed mouse Saa (CEJ Saa isoform) in C57BL/6 mice using adenoviral-mediated gene transfer (17). HDL from these mice was enriched in Saa, as is typical for acute phase HDL, with SAA being the second most abundant apolipoprotein (6). The presence of SAA on HDL had little effect on association with SR-BI. Previous studies reported a marked increase in binding affinity of acute phase HDL to macrophages (11, 12, 27) and decreased binding affinity to hepatocytes (12). These studies did not address specific SR-BI interactions, and the known ability of SAA to bind to proteoglycans on the cell surface complicates interpretation. No major differences in specific binding to SR-BI were observed in our studies between AdSAA-HDL and control HDL.

Interestingly, SAA exhibited a significant inhibitory effect on selective CE uptake, with SAA-enriched HDL showing an ~2-fold lower rate of selective uptake than control HDL. The mechanism of this apparent inhibition by SAA is not known. The CE content of AdSAA-HDL is reduced ~2-fold compared with normal mouse HDL, but changes in the CE content of HDL particles are not thought to influence the rate of selective uptake by SR-BI (47). As discussed below, free SAA was found to exert a marked inhibitory effect on SR-BI association and selective uptake of HDL; it is possible that the decreased selective uptake of AdSAA-HDL may be due to SAA being released from these particles. It is possible that other structural or compositional differences between the different HDLs may account for their differences in selective uptake efficiency. In macrophages, acute phase HDL (isolated from C57BL/6 mice injected with lipopolysaccharide) served as a more efficient particle for selective uptake than normal HDL (40). In contrast, in hepatocytes selective uptake was lower from acute phase HDL than from control HDL (48). However, in these studies the specific contribution of SR-BI or SAA to selective uptake was not addressed (40, 48). Our finding that SR-BI-specific selective uptake was reduced from AdSAA-HDL is consistent with the findings in hepatocytes that show reduced selective uptake from acute phase HDL. This suggests that the presence of SAA, rather than other inflammation-induced changes that may occur in HDL during the acute phase, may underlie the change in selective uptake activity.

A striking finding in our studies was that addition of lipid-free SAA to HDL resulted in a marked inhibition of HDL binding and selective lipid uptake by SR-BI. Thus, at relatively low concentrations (10 µg/ml and lower), SAA (but not apoA-I) inhibited HDL association with SR-BI as well as selective lipid uptake. The mechanism of inhibition by SAA is not yet clear but appears to be distinct from its ability, as described above, to modulate HDL-selective uptake when present on HDL. The inhibition of binding at 4 °C by SAA strongly indicated that inhibition was independent of receptor or ligand internalization and not the result of changes in the cellular content or surface expression of SR-BI. Another possibility is that the addition of SAA to HDL may result in remodeling of HDL particles because it is known that SAA can displace apoA-I from HDL in vitro (6). For example, displacement of labeled apoA-I by SAA could lead to a decrease in apoA-I binding because lipid-free apolipoprotein A-I bind poorly to SR-BI (28, 49). Larger particles also bind SR-BI more tightly (28, 30), whereas pre-{beta} HDLs are poor substrates for SR-BI (28). However, our finding that the inhibitory effect of SAA was largely abolished by preincubation of SAA with the labeled HDL ligand before addition to CHO-SR-BI cells argues against HDL remodeling as a mechanism. Alternatively, lipid-free SAA may exert its effect through its ability to bind directly to SR-BI, thereby inhibiting HDL interaction with SR-BI. We have postulated that lipoprotein-free SAA exerts an inhibitory effect on SR-BI within the confines of the space of Disse, into which it is likely to be secreted in a lipid-free form (50).

Infection and inflammation are associated with a reduction in plasma HDL, and it has often been assumed that the marked increase in SAA content in HDL is responsible for this reduction. However, this is unlikely because the decrease in HDL is rapid and precedes the increase in SAA (51). Furthermore, an increased expression of SAA in the absence of infection or inflammation does not decrease plasma HDL (52). Our studies did show that SAA exerts a significant inhibitory effect on SR-BI binding and selective CE uptake. Such an effect manifested in the liver would not be expected to reduce HDL levels but would be expected to decrease reverse cholesterol transport to the liver. SR-BI expression itself is decreased during the acute phase response (53), which would contribute further to a reduction in reverse cholesterol transport. Thus, SAA may function during the acute phase response to limit reverse cholesterol transport and promote net delivery and retention of cholesterol at sites of tissue repair.

In conclusion, our findings indicated that SR-BI plays a key role in SAA metabolism through its ability to interact with and internalize SAA and, further, that SAA influences HDL cholesterol metabolism through its inhibitory effects on SR-BI-mediated selective lipid uptake.


   FOOTNOTES
 
* This work was supported by National Institutes of Health Grants HL-63763 and HL-65730 (to D. R. v. d. W.) and AG-17237 (to F. C. d. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed: Dept. of Internal Medicine and Graduate Center for Nutritional Sciences, Wethington Health Science Bldg. 541, 900 S. Limestone St., Lexington, KY 40536. Tel.: 859-323-4933 (ext. 81397); Fax: 859-323-5707; E-mail: dvwest1{at}uky.edu.

1 The abbreviations used are: SAA, serum amyloid A; AdSAA, adenovirus SAA; HDL, high density lipoprotein; rHDL, reconstituted HDL; CE, cholesterol ester; SR-BI, scavenger receptor class B type I; LDL, low density lipoprotein; BSA, bovine serum albumin; CHO, Chinese hamster ovary. Back


   ACKNOWLEDGMENTS
 
We thank Wei Shi, Nathan Whitaker, and Jason Cupp for excellent technical assistance. We also thank Dr. Nancy Webb for critical discussions and the SAA adenovirus.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Uhlar, C. M., and Whitehead, A. S. (1999) Eur. J. Biochem. 265, 501-523[Medline] [Order article via Infotrieve]
  2. Kisilevsky, R., and Tam, S. P. (2002) Pediatr. Pathol. Mol. Med. 21, 291-305[CrossRef][Medline] [Order article via Infotrieve]
  3. Sipe, J. (1999) Amyloid 6, 67-70[Medline] [Order article via Infotrieve]
  4. Ramadori, G., Sipe, J. D., and Colten, H. R. (1985) J. Immunol. 135, 3645-3647[Medline] [Order article via Infotrieve]
  5. de Beer, M. C., Yuan, T., Kindy, M. S., Asztalos, B. F., Roheim, P. S., and de Beer, F. C. (1995) J. Lipid Res. 36, 526-534[Abstract]
  6. Coetzee, G. A., Strachan, A. F., van der Westhuyzen, D. R., Hoppe, H. C., Jeenah, M. S., and de Beer, F. C. (1986) J. Biol. Chem. 261, 9644-9651[Abstract/Free Full Text]
  7. Su, S. B., Gong, W., Gao, J. L., Shen, W., Murphy, P. M., Oppenheim, J. J., and Wang, J. M. (1999) J. Exp. Med. 189, 395-402[Abstract/Free Full Text]
  8. Hayat, S., and Raynes, J. G. (1997) Biochem. Soc. Trans. 25, 348S[Medline] [Order article via Infotrieve]
  9. Tam, S. P., Flexman, A., Hulme, J., and Kisilevsky, R. (2002) J. Lipid Res. 43, 1410-1420[Abstract/Free Full Text]
  10. Kisilevsky, R., and Tam, S. P. (2003) J. Lipid Res. 44, 2257-2269[Abstract/Free Full Text]
  11. Banka, C. L., Yuan, T., de Beer, M. C., Kindy, M., Curtiss, L. K., and de Beer, F. C. (1995) J. Lipid Res. 36, 1058-1065[Abstract]
  12. Kisilevsky, R., and Subrahmanyan, L. (1992) Lab. Investig. 66, 778-785[Medline] [Order article via Infotrieve]
  13. Liang, J. S., Schreiber, B. M., Salmona, M., Phillip, G., Gonnerman, W. A., de Beer, F. C., and Sipe, J. D. (1996) J. Lipid Res. 37, 2109-2116[Abstract]
  14. Rigotti, A., Miettinen, H. E., and Krieger, M. (2003) Endocr. Rev. 24, 357-387[Abstract/Free Full Text]
  15. Connelly, M. A., and Williams, D. L. (2004) Curr. Opin. Lipidol. 15, 287-295[CrossRef][Medline] [Order article via Infotrieve]
  16. de Beer, M. C., de Beer, F. C., McCubbin, W. D., Kay, C. M., and Kindy, M. S. (1993) J. Biol. Chem. 268, 20606-20612[Abstract/Free Full Text]
  17. Webb, N. R., de Beer, M. C., van der Westhuyzen, D. R., Kindy, M. S., Banka, C. L., Tsukamoto, K., Rader, D. L., and de Beer, F. C. (1997) J. Lipid Res. 38, 1583-1590[Abstract]
  18. Webb, N. R., Connell, P. M., Graf, G. A., Smart, E. J., de Villiers, W. J., de Beer, F. C., and van der Westhuyzen, D. R. (1998) J. Biol. Chem. 273, 15241-15248[Abstract/Free Full Text]
  19. Strachan, A. F., de Beer, F. C., van der Westhuyzen, D. R., and Coetzee, G. A. (1988) Biochem. J. 250, 203-207[Medline] [Order article via Infotrieve]
  20. de Beer, M. C., Castellani, L. W., Cai, L., Stromberg, A. J., de Beer, F. C., and van der Westhuyzen, D. R. (2004) J. Lipid Res. 45, 706-715[Abstract/Free Full Text]
  21. de Beer, M. C., Durbin, D. M., Cai, L., Mirocha, N., Jonas, A., Webb, N. R., de Beer, F. C., and van der Westhuyzen, D. R. (2001) J. Biol. Chem. 276, 15832-15839[Abstract/Free Full Text]
  22. Matz, C. E., and Jonas, A. (1982) J. Biol. Chem. 257, 4535-4540[Abstract/Free Full Text]
  23. Xu, S., Laccotripe, M., Huang, X., Rigotti, A., Zannis, V. I., and Krieger, M. (1997) J. Lipid Res. 38, 1289-1298[Abstract]
  24. Acton, S., Rigotti, A., Landschulz, K. T., Xu, S., Hobbs, H. H., and Krieger, M. (1996) Science 271, 518-520[Abstract]
  25. Peng, Y., Akmentin, W., Connelly, M. A., Lund-Katz, S., Phillips, M. C., and Williams, D. L. (2004) Mol. Biol. Cell 15, 384-396[Abstract/Free Full Text]
  26. Eckhardt, E. R., Cai, L., Sun, B., Webb, N. R., and van der Westhuyzen, D. R. (2004) J. Biol. Chem. 279, 14372-14381[Abstract/Free Full Text]
  27. Khovidhunkit, W., Shigenaga, J. K., Moser, A. H., Feingold, K. R., and Grunfeld, C. (2001) J. Lipid Res. 42, 967-975[Abstract/Free Full Text]
  28. Liadaki, K. N., Liu, T., Xu, S., Ishida, B. Y., Duchateaux, P. N., Krieger, J. P., Kane, J., Krieger, M., and Zannis, V. I. (2000) J. Biol. Chem. 275, 21262-21271[Abstract/Free Full Text]
  29. Gabay, C., and Kushner, I. (1999) N. Engl. J. Med. 340, 448-454[Free Full Text]
  30. de Beer, M. C., Durbin, D. M., Cai, L., Jonas, A., de Beer, F. C., and van der Westhuyzen, D. R. (2001) J. Lipid Res. 42, 309-313[Abstract/Free Full Text]
  31. Williams, D. L., de La Llera-Moya, M., Thuahnai, S. T., Lund-Katz, S., Connelly, M. A., Azhar, S., Anantharamaiah, G. M., and Phillips, M. C. (2000) J. Biol. Chem. 275, 18897-18904[Abstract/Free Full Text]
  32. Turnell, W., Sarra, R., Glover, I. D., Baum, J. O., Caspi, D., Baltz, M. L., and Pepys, M. B. (1986) Mol. Biol. Med. 3, 387-407[Medline] [Order article via Infotrieve]
  33. Wustner, D., Mondal, M., Huang, A., and Maxfield, F. R. (2004) J. Lipid Res. 45, 427-437[Abstract/Free Full Text]
  34. Silver, D. L., Wang, N., Xiao, X., and Tall, A. R. (2001) J. Biol. Chem. 276, 25287-25293[Abstract/Free Full Text]
  35. Azhar, S., and Reaven, E. (2002) Mol. Cell. Endocrinol. 195, 1-26[CrossRef][Medline] [Order article via Infotrieve]
  36. Gillotte-Taylor, K., Boullier, A., Witztum, J. L., Steinberg, D., and Quehenberger, O. (2001) J. Lipid Res. 42, 1474-1482[Abstract/Free Full Text]
  37. Rhainds, D., Falstrault, L., Tremblay, C., and Brissette, L. (1999) Eur. J. Biochem. 261, 227-235[Medline] [Order article via Infotrieve]
  38. Van Lenten, B. J., Navab, M., Shih, D., Fogelman, A. M., and Lusis, A. J. (2001) Trends Cardiovasc. Med. 11, 155-161[CrossRef][Medline] [Order article via Infotrieve]
  39. Kisilevsky, R., Szarek, W. A., Ancsin, J., Bhat, S., Li, Z., and Marone, S. (2003) J. Mol. Neurosci. 20, 291-297[CrossRef][Medline] [Order article via Infotrieve]
  40. Artl, A., Marsche, G., Lestavel, S., Sattler, W., and Malle, E. (2000) Arterioscler. Thromb. Vasc. Biol. 20, 763-772[Abstract/Free Full Text]
  41. Rocken, C., and Kisilevsky, R. (1997) Amyloid 259-273
  42. Hirano, K., Yamashita, S., Nakagawa, Y., Ohya, T., Matsuura, F., Tsukamoto, K., Okamoto, Y., Matsuyama, A., Matsumoto, K., Miyagawa, J., and Matsuzawa, Y. (1999) Circ. Res. 85, 108-116[Abstract/Free Full Text]
  43. Hoffman, J. S., and Benditt, E. P. (1983) J. Clin. Investig. 71, 926-934
  44. Kluve-Beckerman, B., Yamada, T., Hardwick, J., Liepnieks, J. J., and Benson, M. D. (1997) Biochem. J. 322, Pt. 2, 663-669
  45. Wang, N., Arai, T., Ji, Y., Rinninger, F., and Tall, A. R. (1998) J. Biol. Chem. 273, 32920-32926[Abstract/Free Full Text]
  46. Bausserman, L. L., Saritelli, A. L., Van Zuiden, P., Gollaher, C. J., and Herbert, P. N. (1987) J. Biol. Chem. 262, 1583-1589[Abstract/Free Full Text]
  47. Rodrigueza, W. V., Thuahnai, S. T., Temel, R. E., Lund-Katz, S., Phillips, M. C., and Williams, D. L. (1999) J. Biol. Chem. 274, 20344-20350[Abstract/Free Full Text]
  48. Artl, A., Marsche, G., Pussinen, P., Knipping, G., Sattler, W., and Malle, E. (2002) Int. J. Biochem. Cell Biol. 34, 370-381[CrossRef][Medline] [Order article via Infotrieve]
  49. Webb, N. R., Cai, L., Ziemba, K. S., Yu, J., Kindy, M. S., van der Westhuyzen, D. R., and de Beer, F. C. (2002) J. Lipid Res. 43, 1890-1898[Abstract/Free Full Text]
  50. Morrow, J. F., Stearman, R. S., Peltzman, C. G., and Potter, D. A. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 4718-4722[Abstract/Free Full Text]
  51. Ly, H., Francone, O. L., Fielding, C. J., Shigenaga, J. K., Moser, A. H., Grunfeld, C., and Feingold, K. R. (1995) J. Lipid Res. 36, 1254-1263[Abstract]
  52. Hosoai, H., Webb, N. R., Glick, J. M., Tietge, U. J., Purdom, M. S., de Beer, F. C., and Rader, D. J. (1999) J. Lipid Res. 40, 648-653[Abstract/Free Full Text]
  53. Buechler, C., Ritter, M., Quoc, C. D., Agildere, A., and Schmitz, G. (1999) Biochem. Biophys. Res. Commun. 262, 251-254[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
N. Cheng, R. He, J. Tian, P. P. Ye, and R. D. Ye
Cutting Edge: TLR2 Is a Functional Receptor for Acute-Phase Serum Amyloid A
J. Immunol., July 1, 2008; 181(1): 22 - 26.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
L. Bjorkman, J. Karlsson, A. Karlsson, M.-J. Rabiet, F. Boulay, H. Fu, J. Bylund, and C. Dahlgren
Serum amyloid A mediates human neutrophil production of reactive oxygen species through a receptor independent of formyl peptide receptor like-1
J. Leukoc. Biol., February 1, 2008; 83(2): 245 - 253.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Westerterp, J. F.P. Berbee, N. M.M. Pires, G. J.D. van Mierlo, R. Kleemann, J. A. Romijn, L. M. Havekes, and P. C.N. Rensen
Apolipoprotein C-I Is Crucially Involved in Lipopolysaccharide-Induced Atherosclerosis Development in Apolipoprotein E Knockout Mice
Circulation, November 6, 2007; 116(19): 2173 - 2181.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
Y. Zhao, S. Zhou, and C.-K. Heng
Impact of Serum Amyloid A on Tissue Factor and Tissue Factor Pathway Inhibitor Expression and Activity in Endothelial Cells
Arterioscler. Thromb. Vasc. Biol., July 1, 2007; 27(7): 1645 - 1650.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Z. Cai, L. Cai, J. Jiang, K.-S. Chang, D. R. van der Westhuyzen, and G. Luo
Human Serum Amyloid A Protein Inhibits Hepatitis C Virus Entry into Cells
J. Virol., June 1, 2007; 81(11): 6128 - 6133.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
Y. Zhang, A. M. Ahmed, N. McFarlane, C. Capone, D. R. Boreham, R. Truant, S. A. Igdoura, and B. L. Trigatti
Regulation of SR-BI-mediated selective lipid uptake in Chinese hamster ovary-derived cells by protein kinase signaling pathways
J. Lipid Res., February 1, 2007; 48(2): 405 - 416.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. G. Vishnyakova, R. Kurlander, A. V. Bocharov, I. N. Baranova, Z. Chen, M.